Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, People's Republic of China.
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Immun Inflamm Dis. 2023 Mar;11(3):e810. doi: 10.1002/iid3.810.
Doxorubicin (DOX) can contribute to severe myocardial injury, and bone marrow stromal cells (BMSC)-exosomes (Exos) improves acute myocardial infarction. Hence, this research investigated whether BMSC-Exos alleviated DOX-induced myocardial injury.
BMSC-derived Exos were isolated and identified, and the optimal concentration of DOX was confirmed. H9C2 cells were treated with DOX and BMSC-Exos or in combination with the protein kinase B (AKT) inhibitor. Reactive oxygen species (ROS) and JC-1 were detected to assess oxidative stress (OS) and mitochondrial membrane damage, respectively. In addition, the expression of pyroptosis-related molecules was measured. The expression of phosphatidylinositol 3 kinase (PI3K)-AKT pathway-related proteins and the phosphorylation and acetylation of forkhead box O1 (Foxo1) in the cell nucleus and cytoplasm were tested. Last, interactions between Foxo1 and gasdermin D (GSDMD) were assessed.
BMSC-Exo treatment increased viability and mitochondrial membrane potential and reduced lactic dehydrogenase release and ROS levels in DOX-treated H9C2 cells. Furthermore, the addition of BMSC-Exos suppressed DOX-induced activation and upregulation of NLRP3 and apoptosis-associated speck-like protein containing A CARD (ASC) and in vitro cleavage of caspase-1, GSDMD, interleukin (IL)-1β, and IL-18 proteins. Additionally, BMSC-Exo treatment enhanced the expression of phosphorylated (p)-PI3K, p-AKT, and p-mTOR in DOX-treated H9C2 cells and the levels of phosphorylated Foxo1 in the cytoplasm of DOX-treated H9C2 cells. Foxo1 was enriched in the promoter region of GSDMD. Moreover, the AKT inhibitor API-2 annulled the effects of BMSC-Exos on OS, pyroptosis, and Foxo1 phosphorylation in DOX-treated H9C2 cells.
BMSC-Exos phosphorylated Foxo1 and inactivated Foxo1 transcription via the PI3K-AKT pathway to diminish GSDMD expression, thus restraining DOX-induced pyroptosis and OS of myocardial cells.
多柔比星(DOX)可导致严重的心肌损伤,骨髓基质细胞(BMSC)-外泌体(Exos)可改善急性心肌梗死。因此,本研究旨在探讨 BMSC-Exos 是否能减轻 DOX 诱导的心肌损伤。
分离并鉴定 BMSC 来源的 Exos,并确定 DOX 的最佳浓度。用 DOX 和 BMSC-Exos 处理 H9C2 细胞或与蛋白激酶 B(AKT)抑制剂联合处理。分别用活性氧(ROS)和 JC-1 检测试剂盒评估氧化应激(OS)和线粒体膜损伤。此外,还检测了细胞焦亡相关分子的表达。检测细胞浆中磷酸肌醇 3 激酶(PI3K)-AKT 通路相关蛋白的表达及核内和细胞质中叉头框 O1(Foxo1)的磷酸化和乙酰化水平。最后,评估 Foxo1 与天冬氨酸特异性半胱氨酸蛋白酶 1(caspase-1)剪切酶家族成员 1(Gasdermin D,GSDMD)之间的相互作用。
BMSC-Exo 处理可增加 DOX 处理的 H9C2 细胞活力和线粒体膜电位,减少乳酸脱氢酶释放和 ROS 水平。此外,BMSC-Exos 的添加抑制了 DOX 诱导的 NLRP3 和凋亡相关斑点样蛋白(ASC)的激活和上调,以及体外 caspase-1、GSDMD、白细胞介素(IL)-1β和 IL-18 蛋白的剪切。此外,BMSC-Exo 处理可增强 DOX 处理的 H9C2 细胞中磷酸化(p)-PI3K、p-AKT 和 p-mTOR 的表达,以及 DOX 处理的 H9C2 细胞中细胞质中 p-Foxo1 的水平。Foxo1 富含 GSDMD 的启动子区域。此外,AKT 抑制剂 API-2 消除了 BMSC-Exos 对 DOX 处理的 H9C2 细胞中 OS、细胞焦亡和 Foxo1 磷酸化的影响。
BMSC-Exo 通过 PI3K-AKT 通路磷酸化 Foxo1 并使 Foxo1 转录失活,从而减少 GSDMD 的表达,抑制 DOX 诱导的心肌细胞焦亡和 OS。